A Bengaluru startup has begun a 10,000-patient Phase 3 trial across 10 Indian hospitals to test whether dogs trained to detect cancer in breath samples, paired with AI analysis, can serve as a low-cost prescreening tool in a country where organized cancer detection is nearly absent.
The trial’s outcome will determine whether Dognosis can launch an at-home test next year for a few thousand rupees. The company claims its service does not require Indian regulatory approval because it is a prescreening tool, not a diagnostic device — a distinction that remains untested by regulators.
Only 0.9% of Indian women surveyed in 2019-2021 had undergone breast cancer screening. The figure, drawn from the country’s 2019-2021 National Family Health Survey, is not a data error. It is the baseline against which every cancer detection innovation in India must be measured — and the reason a two-year-old startup operating from a farm outside Bengaluru is now running one of the most closely watched oncology trials in the region.
Dognosis trains dogs to identify cancer traces in human breath, then layers sensor data and machine learning over the animals’ responses to flag which samples need follow-up. The company’s Phase 2 study, published in the Journal of Clinical Oncology, reported roughly 90% sensitivity for early-stage cancers across more than 20 types. That result, which Dognosis attributes to its own methodology, is now being stress-tested in a larger, asymptomatic population. The gap between a promising controlled study and a deployable screening tool is where most health-tech pilots quietly expire.
The trial that has to survive real-world noise
The Phase 3 study began in April and aims to recruit about 10,000 participants over 12 months. It targets asymptomatic people at higher cancer risk and survivors at risk of recurrence, working through 10 hospitals across India. Flagged individuals receive conventional follow-up — imaging and biopsy — rather than a diagnosis from the dog-and-AI system alone.
Dognosis co-founder Akash Kulgod describes the challenge in terms of scale. “It is like finding a needle in a haystack of who in a population has an undiagnosed case of cancer,” he said. The company’s early backers include Accel India and San Francisco-based Caffeinated Capital, which participated in a $1.5 million pre-seed round in 2024 plus an undisclosed additional amount. Kulgod said the funding should cover operations for two years if the firm sticks to its planned growth trajectory.
The screening gap the company is targeting is stark. India carries the world’s third-highest burden of new cancer cases, with the International Agency for Research on Cancer estimating 1.5 million new cases and more than 900,000 deaths in 2024. Yet national survey data shows lifetime screening rates of 1.9% for cervical cancer among women, 0.9% for breast or oral cancer among women, and 1.2% for oral cancer among men.
Pankaj Chaturvedi, deputy director of the Centre for Cancer Epidemiology at Tata Memorial Centre, offered a calibrated endorsement. Emerging technologies should strengthen existing screening programs, he said, not replace them. The distinction matters because India’s existing programs are themselves thin on the ground.
The workflow that connects a breath sample to a clinical referral is easier seen than read.
A proof-of-concept, not yet a platform
Dognosis sits in early translational science, not established clinical medicine. The Phase 2 result is peer-reviewed, but the field still lacks independent replication in a large asymptomatic population — the standard hurdle before broad credibility. Compared with US or EU cancer-diagnostics work, it is closer to an innovation proof-of-concept than a validated screening platform.
The closest Western analogue is SpotitEarly in New Jersey, which has reported similar canine cancer-detection trial results but has not yet commercialized the technology. The difference is structural. Dognosis is trying to combine dogs with AI-driven sensor analysis and position the product as a low-cost prescreening service for a screening-poor market. SpotitEarly sits closer to a biotech validation and commercialization story.
Kulgod said the test does not require Indian regulatory approval because it is a prescreening tool, not a diagnostic device—a distinction Dognosis claims means only diagnostic devices are regulated in India. That claim, which Dognosis has not had tested by regulators, is load-bearing. If an at-home breath test used on asymptomatic people is later classified differently, launch timing, clinical claims, and marketing language could all shift with it.
The Phase 3 readout — expected after the 12-month recruitment window closes — will determine whether the Phase 2 signal translates into a larger, more diverse population. If it does not, Dognosis remains a promising prescreening pilot rather than a deployable product. The trial is the mechanism that separates the two outcomes.
Beyond the headline
The Bigger Picture
India’s screening gap turns a clever detection method into a systems problem. A tool like this matters less because it is novel than because the country has too few routine touchpoints to catch cancers early, so triage technologies become attractive precisely where standard pathways are weakest.
The Science Gap
The central uncertainty is not whether canine olfaction can work in principle, but whether the signal survives at population scale with acceptable specificity. Phase 2 can show promise; Phase 3 has to prove that promise survives real-world noise, uneven sampling, and the medical cost of false alarms.
The Reach
Caffeinated Capital is the actor to watch, because the mechanism is cross-border venture validation for a health-tech platform that could later seek US deployment. If the trial performs well, the implication is not just a new Indian startup, but a stronger investment case for non-invasive diagnostics aimed at screening bottlenecks.
Four decisions the trial forces, depending on where you sit
With the Phase 3 trial now underway and a commercial launch targeted for next year, the evidence is still forming — but the questions it raises are already specific.
- US-based investor with APAC emerging market exposure
Track the Phase 3 trial’s interim signals and any regulatory classification moves by Indian authorities. The prescreening-versus-diagnostic distinction is the single most consequential variable for Dognosis’s commercial timeline. A reclassification would reset launch assumptions entirely.
- Western health-tech executive considering market entry in India
Dognosis’s regulatory strategy — claiming exemption as a prescreening tool — is a case study in navigating India’s diagnostic-device regime. Before replicating it, verify whether the Central Drugs Standard Control Organization has issued any guidance on at-home prescreening tools used on asymptomatic populations.
- Oncologist or public health researcher focused on global cancer screening
Monitor the Phase 3 readout for specificity data, not just sensitivity. A prescreening tool that generates too many false positives in a low-infrastructure setting can overwhelm follow-up capacity faster than it catches cancers. The trial’s real-world performance on this metric will determine clinical utility.
- Supply chain manager for diagnostic device manufacturers
The logistics of collecting, transporting, and processing breath samples at scale — Dognosis aims for 1 million tests annually — will require partnerships with diagnostic chains and courier networks. Watch for announcements of those partnerships as a leading indicator of operational readiness.
FAQ
How will a positive result be confirmed?
Dognosis says flagged samples receive conventional follow-up, including imaging and biopsy. The system is positioned as a prescreening layer, not a stand-alone diagnosis. The open questions are whether every positive screen goes to a hospital referral, who pays for confirmatory testing, and how false positives are managed in practice.
What does Phase 3 actually need to prove?
The open scientific question is whether the company can preserve sensitivity in a larger, asymptomatic, multi-site population and show enough specificity to avoid overwhelming downstream care. A strong early trial does not answer whether the method can function as a routine screening filter in real clinics.
Is this likely to be regulated like a diagnostic?
The useful follow-up is whether Indian regulators will treat an at-home breath test used for prescreening as a diagnostic device, a wellness product, or a triage service. If the regulatory category changes, launch timing, clinical claims, and marketing language could all change with it.
Explainer
- Phase 3 trial
- A late-stage clinical study designed to confirm a treatment or test’s effectiveness in a large, diverse population before regulatory approval or broad deployment. Phase 3 trials typically compare the intervention against the current standard of care and are the last step before commercialization. Dognosis’s Phase 3 is recruiting asymptomatic high-risk participants, which is a harder test than the symptomatic or mixed populations often used in earlier phases.
- Prescreening
- A preliminary step that identifies individuals at higher risk of a condition, routing them toward confirmatory diagnostic testing rather than providing a definitive diagnosis. Prescreening tools are generally subject to lighter regulation than diagnostic devices in many jurisdictions, including India. The distinction is central to Dognosis’s claim that its breath test does not require regulatory approval.
- Canine olfaction
- The use of dogs’ sense of smell to detect biological markers of disease, including cancer, infections, and metabolic conditions. Dogs have up to 300 million olfactory receptors, compared with roughly 6 million in humans, and can detect volatile organic compounds at concentrations as low as parts per trillion. The challenge for clinical use is standardizing and scaling what has historically been a variable, individual animal skill.
- International Agency for Research on Cancer
- The specialized cancer research agency of the World Health Organization, based in Lyon, France. IARC produces the Globocan database, which provides global estimates of cancer incidence, mortality, and prevalence. Its 2024 estimates for India — 1.5 million new cases and more than 900,000 deaths — are the benchmark figures used to quantify the country’s cancer burden.
- National Family Health Survey
- A large-scale, multi-round survey conducted across India that collects data on health, nutrition, and family welfare indicators. The 2019-2021 round was the fifth in the series and included, for the first time, detailed questions on cancer screening uptake. Its finding that fewer than 2% of Indian women had ever been screened for cervical cancer is the most widely cited statistic on the country’s screening gap.
RELATED STORIES
